

Nadine Mockel-Tenbrinck, Daniela Mauer, Carola Barth, Janina Brauner, Waël Al Rawashdeh, Silke Schult, Olaf Hardt, Georg Rauser, Marion Jurk, Mario Assenmacher, and Andrew D. M. Kaiser  
Miltenyi Biotec GmbH, Bergisch Gladbach, Germany

## Introduction

Automated manufacturing of gene-modified T cells for adoptive T cell therapy requires robust and reproducible processes that are based on materials and reagents that must fulfill strict safety requirements. However, it can be difficult to obtain these materials and reagents in large enough quantities. GMP-compliant human AB serum is one of such reagents, which is, in

most cases, used for potent T cell expansion in culture systems. Therefore, improving methods to generate sufficient numbers of gene-engineered T cells suitable for clinical use, independent of human AB serum, is essential for the commercial scalability of automated cell manufacturing processes.

## Methods

### 1 T Cell Transduction Process on the CliniMACS Prodigy®




Figure 1

## Results

### 1 Fully automated manufacturing of gene-modified T cells

CD4<sup>+</sup>/CD8<sup>+</sup> T cells were automatically enriched, stimulated, and expanded in the CliniMACS Prodigy® (fig. 1). Either the standard TCT Process with 3% human AB serum (n = 11) or a serum-free TCT Process (n = 11) was performed. The T cell

cultures were monitored at different time points to determine cell count (fig. 2A) and viability (fig. 2B). The absolute expansion of viable T cells was calculated afterwards (fig. 2C).




Figure 2

### 2 Quality control

#### Immunophenotype

The cellular composition of enriched CD4<sup>+</sup>/CD8<sup>+</sup> cells manufactured in the CliniMACS Prodigy with 3% human AB serum (n = 11) or serum-free condition (n = 11) was analyzed by flow cytometry using the MACSQuant® Analyzer 10.

Frequencies of different cell types among viable CD45<sup>+</sup> cells were determined for the enriched population (fig. 3A) or the final product automatically generated in the CliniMACS Prodigy (fig. 3B).




Figure 3

#### T cell phenotype

Frequencies of naïve (T<sub>N</sub>), stem cell memory (T<sub>SCM</sub>), central memory (T<sub>CM</sub>), effector memory (T<sub>EM</sub>), and effector T cells (T<sub>EFF</sub>) were analyzed based on CD95, CD62L, and CD45RO

expression in the final product (fig. 4A). The percentages of CD4<sup>+</sup> and CD8<sup>+</sup> T cells were analyzed in the enriched population and the final product (fig. 4B).




Figure 4

#### Transduction efficiency and CAR T cell counts

CAR T cell frequencies in the final product were analyzed for the automatically manufactured CAR T cells (CliniMACS Prodigy) in the presence of 3% human AB serum (n = 8) or under serum-free conditions (n = 8) (fig. 5A).

The absolute numbers of CAR T cells were calculated based on the number of viable T cells of the respective manufacturing run (fig. 5B).



Figure 5

### 3 In vitro functionality of CAR T cells

The functionality of gene-engineered CAR T cells was assessed based on a cell killing assay. Specific cell lysis was determined by coculture of target cells with CAR T cells at the indicated effector-to-target cell (E:T) ratios for 24 hours

(fig. 6). CAR T cells were automatically manufactured (CliniMACS Prodigy) either in the presence of 3% human AB serum (n = 6) or under serum-free conditions (n = 6).




Figure 6

### 4 In vivo functionality of CAR T cells

Anti-tumor activity of automatically manufactured CAR T cells (CliniMACS Prodigy) either in the presence of 3% human AB serum or under serum-free conditions was analyzed. NSG mice

received 5x10<sup>5</sup> target cells (i.v.). After tumor engraftment (7 days) 1x10<sup>6</sup> CAR T cells or mock T cells were injected and tumor growth was measured at the indicated time points (fig. 7).




Figure 7

## Conclusion

- The T Cell Transduction (TCT) process developed on the CliniMACS Prodigy platform enables robust manufacturing of gene-modified T cells without the need for serum supplementation.
- T cell numbers, viability, and phenotype were comparable between the serum-free TCT process and a standard process which relies on 3% human AB serum.
- Lentiviral transduction in the absence of serum led to an increased efficiency of gene modification resulting in larger CAR T cell numbers. CAR T cells were fully functional *in vitro* and *in vivo*.

These improvements are another step towards simplified, fully automated manufacture of CAR T cells, designed for the treatment of a large number of patients, at a commercial scale.

#### Funding

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 667980.

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. MACS® GMP Products are for research use and *ex vivo* cell culture processing only, and are not intended for human *in vivo* applications. For regulatory status in the USA, please contact your local representative. MACS GMP Products are manufactured and tested under a quality system certified to ISO 13485 and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials. The CliniMACS® System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485. In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for *in vitro* use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans the national legislation and regulations – e.g. for the EU the Directive 2004/23/EC ("human tissues and cells"), or the Directive 2002/98/EC ("human blood and blood components") – must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System. In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved; all other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application or Investigational Device Exemption (IDE). CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use. In the US, the CliniMACS Prodigy® T Cell Transduction Process is available for research use only. CliniMACS, CliniMACS Prodigy, MACS, the MACS logo, MACSQuant, TeoMACS, and TransAct are registered trademarks or trademarks of Miltenyi Biotec GmbH and/or its affiliates in various countries worldwide. Copyright © 2017 Miltenyi Biotec GmbH and/or its affiliates. All rights reserved.